Tacrolimus Therapy Among Steroid-Resistant Nephrotic Syndrome Children: A Preliminary Study in West Java, Indonesia
Abstract
Objective: To explore the outcomes of Tac therapy for Steroid-Resistant Nephrotic Syndrome (SRNS) and its implication in reducing the number of CKD events.
Methods: An open, prospective, cohort study was conducted at a tertiary hospital in Bandung, West Java, Indonesia. Children (age 1–18 years old) with steroid and cyclophosphamide resistant nephrotic syndrome were enrolled in this study. Blood pressure, urinary protein, serum ureum, and creatinine levels were measured every month, Tac and soluble urokinase plasminogen activator receptor (supaR) levels were assessed at the 0, third, and sixth months.
Results: Ten of fifteen subjects enrolled in this study got better within 3–6 months with a trend of decreasing suPAR level and proteinuria, as well as stable blood pressure and serum creatinine and ureum level. During treatment, no side effects of the subjects were found with the Tac level maintain safely.
Conclusion: Tac is an effective and safe agent in treating SRNS, especially for those do not respond well to an alkylating agent.
Keywords
Full Text:
PDFReferences
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi:10.1016/j.kint.2021.05.021
- Widiasta A, Wahyudi K, Nugrahapraja H, Sribudiani Y, Rachmadi D. The unique difference between serum level of soluble urokinase plasminogen activator receptor (suPAR) in steroid-resistant nephrotic syndrome children treated with an alkylating agent and calcineurin inhibitors. J Compr Pediatr. 2021;In Press(In Press):e109912. doi:10.5812/compreped.109912
- Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76–87. doi:10.1038/nrneph.2014.216
- Malaga-Dieguez L, Bouhassira D, Gipson D, Trachtman H. Novel therapies for FSGS: preclinical and clinical studies. Adv Chronic Kidney Dis. 2015;22(2):e1–e6. doi:10.1053/j.ackd.2014.10.001
- Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24(8):1517–23. doi:10.1007/s00467-009-1220-z
- Hoefele J, Beck BB, Weber LT, Brinkkötter P. Steroid-resistent nephrotic syndrome. Medizinische Genet. 2018;30:410–21. doi:10.1007/s11825-018-0215-1
- Li X, Li H, Chen J, He Q, Lv R, Lin W, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant. 2008;23(6):1919–25. doi:10.1093/ndt/gfm637
- Moghtaderi M. Continuous Renal Replacement Therapy (CRRT) in Patients with COVID-19 Infection. 2020;8(2):4–7.
- Mousa SO, Saleh SM, Aly HM, Amin MH. Evaluation of serum soluble urokinase plasminogen activator receptor as a marker for steroid-responsiveness in children with primary nephrotic syndrome. Saudi J Kidney Dis Transpl. 2018;29(2):290–96. doi:10.4103/1319-2442.229266
- Stone H, Magella B, Bennett MR. The Search for Biomarkers to Aid in Diagnosis, Differentiation, and Prognosis of Childhood Idiopathic Nephrotic Syndrome. Front Pediatr. 2019;7(October):1–12. doi:10.3389/fped.2019.00404
- Wada T, Nangaku M. A circulating permeability factor in focal segmental glomerulosclerosis: The hunt continues. Clin Kidney J. 2015;8(6):708–15. doi:10.1093/ckj/sfv090
- Winnicki W, Sunder-Plassmann G, Sengölge G, et al. Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method. Sci Rep. 2019;9(1):2–10. doi:10.1038/s41598-019-50405-8
- Widiasta A, Wahyudi K, Nugrahapraja H, Sribudiani Y, Rachmadi D. The unique difference between serum level of soluble urokinase plasminogen activator receptor (suPAR) in steroid-resistant nephrotic syndrome children treated with an alkylating agent and calcineurin inhibitors. J Compr Pediatr. 2021;In Press(In Press). doi:10.5812/compreped.109912
- Falkiewicz K, Kamińska D, Nahaczewska W, et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. Transplant Proc. 2006;38(1):119–22. doi:10.1016/j.transproceed.2005.12.083
- Lim BJ, Yang JW, Do WS, Fogo AB. Pathogenesis of focal segmental glomerulosclerosis. J Pathol Transl Med. 2016;50(6):405–10. doi:10.4132/jptm.2016.09.21
- Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine. A. Nat Med. 2008;14(9):931–8. doi:10.1038/nm.1857
- Widiasta A, Wahyudi K, Sribudiani Y, Rachmadi D. The level of transforming growth factor beta as a possible predictor of cyclophosphamide response in children with steroid-resistant nephrotic syndrome. BioMedicine. 2021;11(3):67–75. doi:10.37796/2211-8039.1205
- Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60. doi:10.1038/nm.2411
- Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, et al. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol. 2018;19(1):361–8.
- Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130–5. doi:10.1038/ki.2012.238
- Widiasta A, Wahyudi K, Sribudiani Y, Rachmadi D. The level of transforming growth factor-β as a possible predictor of cyclophosphamide response in children with steroid-resistant nephrotic syndrome. BioMedicine. 2021;11(3):68–75. doi:10.37796/2211-8039.1205
DOI: https://doi.org/10.15850/ijihs.v12.n2.3663
Article Metrics
Abstract view : 76 timesPDF - 21 times
This Journal indexed by
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
View My Stats